Skip to main content
Fig. 6 | Lipids in Health and Disease

Fig. 6

From: Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non–small-cell lung cancer

Fig. 6

Detection of substantial alterations in the constituents of PI among three distinct groups of patients prior to and subsequent to intervention. A Significant alterations were not observed in the PI levels of the PR group. B The SD group showed a significant increase in PI 38:0, PI 40:2, and PI 44:4 levels after treatment. C In the PD group, more than half of the PIs exhibited a significant up-regulation after treatment. To evaluate the changes in PI levels, a paired two-tailed Student’s t-test was performed within each group (PR, SD, PD). The comparison was made between the non-treatment group and the group treated with a combination of anlotinib and a PD-1 inhibitor. Statistical significance was determined with a P -value of less than 0.05, which was denoted with an asterisk

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X